NYSEAMERICAN : MAIA
MAIA Biotechnology, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.14 USD (Oct 30, 2026, 10:29 AM EDT) · Market cap 69.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 11.54M | 9.72M | 6.95M | 9.07M | 7.24M | 4.29M |
| Research & Development | 17.40M | 14.55M | 10.01M | 11.11M | 8.93M | 3.50M |
| Operating Expenses | 28.95M | 24.27M | 16.96M | 20.18M | 16.18M | 7.79M |
| Operating Income | -28.95M | -24.27M | -16.96M | -20.18M | -16.18M | -7.79M |
| Interest Expense | -57.00 | -6.86K | -6.97K | -827.54K | ||
| Interest & Investment Income | 500.15K | 313.95K | 318.37K | 34.49K | 1.87K | 2.01K |
| Other Non Operating Income (Expenses) | 1.60M | 1.56M | -6.62M | 381.85K | 412.02K | -1.71M |
| EBT Excluding Unusual Items | -26.85M | -22.40M | -23.25M | -19.77M | -15.77M | -10.32M |
| Gain (Loss) on Sale of Investments | -450.58K | |||||
| Other Unusual Items | -2.26M | |||||
| Pretax Income | -26.85M | -22.40M | -23.25M | -19.77M | -16.22M | -12.58M |
| Earnings From Continuing Operations | -26.85M | -22.40M | -23.25M | -19.77M | -16.22M | -12.58M |
| Minority Interest in Earnings | 74.33K | |||||
| Net Income | -26.85M | -22.40M | -23.25M | -19.77M | -16.22M | -12.50M |
| Net Income to Common | -26.85M | -22.40M | -23.25M | -19.77M | -16.22M | -12.50M |
| Shares Outstanding (Basic) | 44.15M | 32.11M | 22.20M | 13.26M | 9.28M | 5.28M |
| Shares Outstanding (Diluted) | 44.15M | 32.11M | 22.20M | 13.26M | 9.28M | 5.28M |
| EPS (Basic) | -0.61 | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 |
| EPS (Diluted) | -0.61 | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 |
| EBIT | -28.95M | -24.27M | -16.96M | -20.18M | -16.18M | -7.79M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 27.60M | 8.66M | 9.60M | 7.15M | 10.95M | 10.57M |
| Cash & Short-Term Investments | 27.60M | 8.66M | 9.60M | 7.15M | 10.95M | 10.57M |
| Other Receivables | 77.35K | 144.68K | 302.79K | 43.67K | ||
| Receivables | 77.35K | 144.68K | 302.79K | 43.67K | ||
| Prepaid Expenses | 641.54K | 1.04M | 473.83K | 268.68K | 554.32K | 54.54K |
| Total Current Assets | 28.24M | 9.70M | 10.15M | 7.56M | 11.81M | 10.67M |
| Long-Term Deferred Charges | 211.20K | 651.58K | ||||
| Other Long-Term Assets | 2.80K | 2.80K | 2.80K | 2.80K | 2.80K | 3.12K |
| Total Assets | 28.24M | 9.70M | 10.16M | 7.57M | 12.02M | 11.33M |
| Accounts Payable | 2.84M | 2.04M | 1.51M | 1.64M | 1.17M | 960.40K |
| Accrued Expenses | 3.42M | 3.80M | 2.32M | 3.30M | 2.10M | 1.19M |
| Total Current Liabilities | 6.26M | 5.84M | 3.83M | 4.94M | 3.27M | 2.15M |
| Other Long-Term Liabilities | 1.31M | 1.49M | 2.69M | 2.15M | 245.34K | |
| Total Liabilities | 7.57M | 7.33M | 6.52M | 7.09M | 3.51M | 2.15M |
| Common Stock | 6.08K | 3.86K | 2.62K | 1.70K | 1.10K | 758.00 |
| Additional Paid-In Capital | 144.65M | 112.05M | 90.90M | 64.47M | 52.73M | 37.62M |
| Retained Earnings | -123.94M | -109.63M | -87.23M | -63.98M | -44.21M | -28.44M |
| Comprehensive Income & Other | -41.69K | -50.23K | -30.61K | -16.26K | -15.97K | |
| Total Common Equity | 20.68M | 2.38M | 3.63M | 477.51K | 8.51M | 9.18M |
| Shareholders' Equity | 20.68M | 2.38M | 3.63M | 477.51K | 8.51M | 9.18M |
| Total Liabilities & Equity | 28.24M | 9.70M | 10.16M | 7.57M | 12.02M | 11.33M |
| Net Cash (Debt) | 27.60M | 8.66M | 9.60M | 7.15M | 10.95M | 10.57M |
| Net Cash Per Share | 0.62 | 0.27 | 0.43 | 0.54 | 1.18 | 2.00 |
| Filing Date Shares Outstanding | 60.83M | 60.67M | 29.59M | 20.00M | 11.00M | 7.94M |
| Total Common Shares Outstanding | 60.82M | 38.62M | 26.16M | 16.99M | 10.96M | 7.58M |
| Working Capital | 21.98M | 3.87M | 6.32M | 2.63M | 8.54M | 8.53M |
| Book Value Per Share | 0.34 | 0.06 | 0.14 | 0.03 | 0.78 | 1.21 |
| Tangible Book Value | 20.68M | 2.38M | 3.63M | 477.51K | 8.51M | 9.18M |
| Tangible Book Value Per Share | 0.34 | 0.06 | 0.14 | 0.03 | 0.78 | 1.21 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -26.85M | -22.40M | -23.25M | -19.77M | -16.22M | -12.50M |
| Other Amortization | 596.95K | |||||
| Stock-Based Compensation | 2.83M | 2.63M | 1.91M | 3.09M | 2.32M | 2.72M |
| Other Operating Activities | -18.87K | -579.40K | 6.88M | 526.53K | 1.45M | 3.94M |
| Change in Accounts Payable | 1.11M | 519.72K | -118.83K | 471.90K | 211.35K | 805.52K |
| Change in Other Net Operating Assets | 354.26K | 979.60K | -1.12M | 2.61M | 141.44K | 320.23K |
| Operating Cash Flow | -22.57M | -18.84M | -15.70M | -13.07M | -12.10M | -4.12M |
| Long-Term Debt Issued | 7.43M | |||||
| Short-Term Debt Repaid | -367.00 | |||||
| Total Debt Repaid | -367.00 | |||||
| Net Debt Issued (Repaid) | 7.43M | |||||
| Issuance of Common Stock | 42.32M | 18.52M | 18.97M | 11.42M | 14.44M | 6.60M |
| Other Financing Activities | -2.30M | -617.13K | -795.26K | -2.15M | -1.97M | |
| Financing Cash Flow | 40.02M | 17.91M | 18.18M | 9.27M | 12.48M | 14.03M |
| Foreign Exchange Rate Adjustments | -4.78K | -5.22K | -21.55K | -117.00 | -4.43K | |
| Net Cash Flow | 17.45M | -943.27K | 2.45M | -3.80M | 376.63K | 9.91M |
| Levered Free Cash Flow | -13.79M | -11.02M | -9.93M | -7.42M | -7.43M | -1.59M |
| Unlevered Free Cash Flow | -13.79M | -11.02M | -9.93M | -7.41M | -7.43M | -1.67M |
| Change in Working Capital | 1.46M | 1.50M | -1.24M | 3.09M | 352.78K | 1.13M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 67.52M | 58.55M | 51.79M | 19.82M | 38.42M | |
| Enterprise Value | 39.92M | 47.65M | 43.10M | 13.72M | 24.36M | |
| Last Close Price | 1.10 | 1.53 | 1.98 | 1.17 | 3.51 | |
| PB Ratio | 3.24 | 24.64 | 14.25 | 41.52 | 4.52 | |
| P/TBV Ratio | 3.24 | 24.64 | 14.25 | 41.52 | 4.52 | |
| Net Debt / Equity Ratio | -1.33 | -3.64 | -2.64 | -14.97 | -1.29 | -1.15 |
| Quick Ratio | 4.41 | 1.48 | 2.53 | 1.48 | 3.44 | 4.95 |
| Current Ratio | 4.51 | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 |
| Return on Equity (ROE) | -218.68% | -745.24% | -1,131.02% | -440.12% | -183.39% | -332.54% |
| Return on Assets (ROA) | -92.10% | -152.75% | -119.61% | -128.79% | -86.60% | -80.62% |
| Return on Capital Employed (ROCE) | -131.70% | -627.40% | -268.10% | -767.50% | -184.80% | -84.80% |
| Earnings Yield | -54.77% | -38.25% | -44.90% | -99.74% | -42.22% | |
| Buyback Yield / Dilution | -65.07% | -44.68% | -67.38% | -42.95% | -75.75% | -19.23% |